Terms: = Ovarian cancer AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4 AND Treatment
8931 results:
1. Synchronous skull base and spinal metastases in a patient with treatment-resistant, high-grade serous adenocarcinoma of tubo-ovarian origin.
Ziegler J; El-Shakankery KH; Hyare H; Flynn M
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772871
[TBL] [Abstract] [Full Text] [Related]
2. Racial and Ethnic Inequities in cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
Islam JY; Hathaway CA; Hume E; Turner K; Hallanger-Johnson J; Tworoger SS; Camacho-Rivera M
JAMA Netw Open; 2024 May; 7(5):e2412050. PubMed ID: 38767916
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of secular trends of three major gynecologic cancers burden and attributable risk factors from 1990 to 2019: an age period cohort analysis.
Liu Y; Shi W; Mubarik S; Wang F
BMC Public Health; 2024 May; 24(1):1349. PubMed ID: 38764017
[TBL] [Abstract] [Full Text] [Related]
4. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
[TBL] [Abstract] [Full Text] [Related]
5. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
6. The Role of Palliative Surgery in the Management of Acute Intestinal Obstruction Secondary to Peritoneal Carcinomatosis.
Bhat BK; Yadav A; Nundy S
Chirurgia (Bucur); 2024 Apr; 119(2):218-226. PubMed ID: 38743835
[No Abstract] [Full Text] [Related]
7. Vitamins in Gynecologic Malignancies.
Wierzbowska N; Olszowski T; Chlubek D; Kozłowski M; Cymbaluk-Płoska A
Nutrients; 2024 May; 16(9):. PubMed ID: 38732639
[TBL] [Abstract] [Full Text] [Related]
8. Germline biallelic brca2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
9. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
[TBL] [Abstract] [Full Text] [Related]
10. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF; Manning-Geist BL; Zhou Q; Soumerai T; Holland A; Da Cruz Paula A; Green H; Ozsoy MA; Iasonos A; Hollmann T; Leitao MM; Mueller JJ; Makker V; Tew WP; O'Cearbhaill RE; Liu YL; Rubinstein MM; Troso-Sandoval T; Lichtman SM; Schram A; Kyi C; Grisham RN; Causa Andrieu P; Wherry EJ; Aghajanian C; Weigelt B; Hensley ML; Zamarin D
Nat Med; 2024 May; 30(5):1330-1338. PubMed ID: 38653864
[TBL] [Abstract] [Full Text] [Related]
11. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
12. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
13. Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients.
Straubhar AM; Stroup C; Manorot A; McCool K; Rolston A; Reynolds RK; McLean K; de Bear O; Siedel J; Uppal S
Int J Gynecol Cancer; 2024 May; 34(5):745-750. PubMed ID: 38642924
[TBL] [Abstract] [Full Text] [Related]
14. Germline mutations in BRCA1 and brca2 among Brazilian women with ovarian cancer treated in the Public Health System.
de Oliveira Ferreira C; Carneiro VCG; Araujo Mariz C
BMC Cancer; 2024 Apr; 24(1):499. PubMed ID: 38641594
[TBL] [Abstract] [Full Text] [Related]
15. Imaging for local recurrence of breast cancer.
Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
[TBL] [Abstract] [Full Text] [Related]
16. A Study on the Retrospective Reinterpretation of BRCA1 and brca2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
17. A 14-year-old girl with premature ovarian insufficiency but with a positive pregnancy test.
Touwslager RNH; Zwaan CM; Bakker B; Lentjes EGWM; Looijenga LHJ; van Santen HM
J Pediatr Endocrinol Metab; 2024 May; 37(5):482-485. PubMed ID: 38618883
[TBL] [Abstract] [Full Text] [Related]
18. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract] [Full Text] [Related]
19. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
20. Common misconceptions and myths about ovarian cancer causation: a national cross-sectional study from palestine.
Elshami M; Jaber I; Alser M; Al-Slaibi I; Jabr H; Ubaiat S; Tuffaha A; Khader S; Khraishi R; Arafeh ZA; Al-Madhoun S; Alqattaa A; Yaseen A; El Hadi AA; Barhoush O; Hijazy M; Eleyan T; Alser A; Hziema AA; Shatat A; Almakhtoob F; Mohamad B; Farhat W; Abuamra Y; Mousa H; Adawi R; Musallam A; Albarqi SI; Abu-El-Noor N; Bottcher B
BMC Public Health; 2024 Apr; 24(1):1027. PubMed ID: 38609950
[TBL] [Abstract] [Full Text] [Related]
[Next]